IO Biotech USA
- Biotech or pharma, therapeutic R&D
IO Biotech’s (Oncology Focused Co.) most advanced program Cylembio (IO102-IO103) is currently in global phase 3 development (fully enrolled) for 1L advanced melanoma. Also Ph2 is ongoing in NSCLC & SCCHN; and perioperative neo/adjuvant set up of melanoma and Head & Neck
)
)
)
)
){kind=logo}
){kind=logo}
)
){kind=logo}
)
){kind=logo}
){kind=logo}